Anti-psychotic Medication (Stable Dose) Weight Loss Study

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Obesity

In brief

This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have been taking a stable dose of certain anti-psychotic medications for longer than three months.

Key facts

Study ID

NCT01272765

Run by

Avera McKennan Hospital & University Health Center

People needed

0

Starts

2012-03-01

Expected to finish

2013-01-01

Last updated by the study team

2012-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women, age 18 and older
• Agree to keep diet, exercise and all current health habits stable during participation in the study
• Currently on a stable dose of Risperdal (Risperidone), Seroquel (Quetiapine) and/or Zyprexa (Olanzapine) for at least three months

You may not qualify if…

• Current active acute psychotic episode
• Women who are pregnant, breastfeeding, or planning to become pregnant
• Prior bariatric surgery
• Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month
• Obesity as a result of a clinically-diagnosed endocrine problem

Where it is running

• Avera Research Institute — Sioux Falls, South Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.